Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003867 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00003867 is a Phase 1 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT00003867, a Phase 1 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors that have not responded to previous treatment.
Interventions
- DRUG capecitabine
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-03 |
| Est. Completion | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003867
The ClinicalTrials.gov registry entry for NCT00003867 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00003867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003867 about?
NCT00003867 is a clinical study titled "Irinotecan and Capecitabine in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating patients who have solid tumors...
What is the current status of trial NCT00003867?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1999-03. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00003867?
The interventions under investigation include: capecitabine (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003867?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.